leukaemia
Roche and Pharmacyclics agree leukaemia pact
October 17, 2014Research and Development, Sales and Marketing BMS, CLL, Cancer, Gazyva, Pharmacyclics, Roche, imbruvica, leukaemia
Pharmacyclics’s cancer drug Imbruvica will be tested in combination with Roche’s Gazyva in a new partnership announced by the firms. …
EMA keeps Ariad cancer drug on the market
October 13, 2014Sales and Marketing Ariad, CML, EMA, PRAC, iclusig, leukaemia, ponatinib
The EMA has recommended Ariad’s leukaemia drug Iclusig (ponatinib) should continue to be used under its current indication despite ongoing …
Boehringer blood cancer drug scores in Phase II
July 9, 2014Research and Development, Sales and Marketing Boehringer, blood, giotrif, leukaemia, volasertib
Less than a year after securing its first cancer drug on the market with Giotrif, Boehringer has taken another decisive …
FDA breakthrough for Amgen
July 2, 2014Research and Development, Sales and Marketing Amgen, BiTE antibody blinatumomab, FDA, all, leukaemia
Amgen has taken a major step down the road to getting its investigational cancer drug blinatumomab onto the market after …
FDA extends licence for Janssen’s Imbruvica
February 13, 2014Sales and Marketing FDA, Janssen, durect, imbruvica, leukaemia
Janssen and partner Pharmacyclics have been given an extended FDA approval for their new blood cancer treatment Imbruvica. The US …
EMA in new Iclusig probe
December 9, 2013Sales and Marketing Ariad, EMA, iclusig, leukaemia
Europe’s medicines regulator has begun a new review of Ariad Pharmaceuticals’ leukaemia drug Iclusig, looking in particular at the risk …
Ariad cancer drug pulled amid safety fears
November 1, 2013Sales and Marketing Ariad, FDA, iclusig, leukaemia
Ariad Pharmaceuticals has been forced by the FDA to suspend sales of its blood cancer drug Iclusig given the high …
New Roche leukaemia drug beats rival
July 24, 2013Research and Development, Sales and Marketing Rituxan, Roche, leukaemia, obinutuzumab
Roche’s next generation leukaemia drug obinutuzumab has beaten the firm’s ageing blood cancer medicine Rituxan in a late-stage trial. The …
Roche leukaemia drug granted speedy US review
July 3, 2013Research and Development, Sales and Marketing CLL, FDA, Roche, leukaemia, obinutuzumab
Roche’s investigational leukaemia drug could be available for US patients by the end of the year as the FDA looks …
Ariad expands in Europe
February 22, 2013Sales and Marketing Ariad, leukaemia, leukemia
The new European boss of Ariad Pharmaceuticals has sketched out the US firm’s plans for its next-generation leukaemia drug, which …
Blood cancer charity to kick-start clinical trials
May 19, 2011Research and Development Cancer, blood cancer, clinical trials, leukaemia
A UK blood cancer charity is creating a network of clinical trial centres with backing from the NIHR Clinical Research …
Leukaemia drug fast-tracked by NICE
January 6, 2011Sales and Marketing Bendamustine, Levact, NICE, Napp, chronic lymphocytic leukaemia, leukaemia
A treatment for patients with the most common form of leukaemia has been fast tracked by NICE because of strong …
Quarter of all cancers found at late stage
November 15, 2010Cancer, England, NCIN, NHS, National Cancer Intelligence Network, brain cancer, cancer diagnosis, leukaemia
Nearly a quarter of all cancer diagnoses in England came after a patient had been admitted to hospital for emergency …
Tasigna more effective than Glivec, says Novartis
June 21, 2010Research and Development, Sales and Marketing Glivec, Novartis, Tasigna, leukaemia
Novartis has gained US approval for Tasigna to be used as a front line treatment for chronic myeloid leukaemia. The …
Antisoma stages comeback with promising cancer drugs
May 20, 2010Research and Development AML, Antisoma, chemotherapy, leukaemia
UK biotech Antisoma is looking to put previous late-stage trial failures behind it by focusing on two new cancer drugs. …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
